



Agenda for Cancer Research KI Executive Board

Tuesday the 30th of January 2024, 15:00-17:00

Online meeting: <https://ki-se.zoom.us/j/65483417206>

(IP= information point, D=discussion point, DP=Decision point)

Board members	<p>Chair and Director Elias Arnér, Department of Medical Biochemistry and Biophysics Co-Director Yvonne Wengström, Department of Neurobiology, Care Sciences and Society Co-Director Marco Gerling, Department of Biosciences and Nutrition Simon Ekman, Department of Oncology-Pathology (Joined 15:45) Linda Lindström, Department of Oncology-Pathology Päivi Östling, Department of Oncology-Pathology, SciLifeLab Margareta Wilhelm, Department of Microbiology, Tumor and Cell Biology Matthias Löhr, Department of Clinical Science, Intervention and Technology (Joined 15:12, Left at 16:00) Renske Altena, Department of Oncology-Pathology (Joined 15:30) Keith Humphreys, Department of Medical Epidemiology and Biostatistics Ninib Baryawno, Department of Women's and Children's Health, Junior faculty representative (Joined 15:35) Eva Jolly, Karolinska Comprehensive Cancer Centre coordinator (Joined 15:06) Jonas Fuxe, Department of Laboratory Medicine, Reference Group Chair (Joined 15:00) Sara Abu Ajamieh, Department of Women's and Children's Health, Junior faculty representative (Left at 16:00) Lise-lott Eriksson, Chair of the Blood Cancer Forum, Patient Group Dina Dabaghie, Department of Medical Biochemistry and Biophysics Liselotte Bäckdahl, Department of Medical Biochemistry and Biophysics</p>
Invited Guests	<p>Svetlana Bajalica Lagercrantz, Barbro Ehlin-Henriksson, Karin Lindberg, NatiOn Research School (point 10), Didn't attend</p>
Board members not attending	<p>Patrik Rossi, Managing Director, Cancer Theme Karolinska University. Lena Sharp, RCC Stockholm-Gotland</p>

- 1) Welcome to the meeting and minutes from the previous CRKI Executive Board meeting 2023-12-14, (E. Arnér, 3 min) DP
 Meeting started 15:01
 E. Arnér welcomed everyone to the meeting, with a short introduction of CRKI and a round table introduction of the attendees.
 Minutes from previous meeting 2023-12-14 were approved.
 Agenda for the meeting was approved.



- 2) Welcome to our new board members: Executive Board intro round IP
- E. Arnér: Director of CRKI, physician at training, professor in biochemistry.
L. Bäckdahl, D.Dabaghie: Administration of CRKI.
Y.Wengström: Co-director, professor of nursing working on exercise oncology and impact of exercise in cancer, member of the steering group in KCCC, leader of WG4 (outreach) in CRKI.
M. Gerling: Co-director, physician in oncology, working on pancreatic cancer, colorectal cancer, liver metastasis, and cell interactions.
K. Humphreys: Professor of biostatistics, working with statistical methods for cancer screening data.
M. Wilhelm: Associate professors in tumor biology, pediatric cancer, leader of WG2 (Education) in CRKI.
S. Abu Ajamieh: PhD student representative, working on neuroblastoma.
P. Östling: Senior Researcher, working on precision cancer medicine and the infrastructure from SciLifeLab in the PCM program.
L. Lindström: Associate professor, working on breast cancer, leader of WG1 (research) in CRKI.
L. Eriksson: Patient representative advocate, blood cancer forum, president of myeloma patient Europa.
E. Jolly: Karolinska Comprehensive Cancer Center coordinator.
M. Löhr: Professor, working on pancreatic cancer.
J. Fuxe: Senior researcher, prefect of labmed, chair of the reference group in CRKI.
R. Altena: Oncologist and associate professor.
N. Baryawno: Docent, working on cancer biology, chair of junior faculty and their representative in CRKI.
S. Ekman: Clinical oncologist, professor of oncology, working on lung cancer preclinical, translational, and clinical, leader of WG5 (industrial collaborations) in CRKI.
- 3) Update EB meeting schedule for the spring (L.Bäckdahl, Dina Dabaghie 5 min) DP
The following days were agreed on for the upcoming EB meetings:
24th of April 14-16, online meeting
21st of May 12-16, in person meeting
- 4) Translational Seed Funding grant results from external evaluation (L.Bäckdahl, E. Arnér, 10 min) DP
- L. Bäckdahl gave an overview of the revision process. 34- applications were received, the internal triage identified 26 applications that were sent for the external review. 3 external reviewers (Peter Nygren Uppsala University, Anna Blom Lund University, Håkan Axelson Lund University) assessed the applications according to the received guidelines and taking in consideration possible conflict of interest. The following were the instructions given to the applicants when applying a) novel project, b) collaborative project between a pre-clinical and a clinical scientist, c)



CVs of both applicants. The ranking was done based on the following criteria: i) scientific quality ii) originality and innovativeness of the proposal iii) merits of the applicants iv) collaborative aspect v) novel collaboration (no existing previous collaborations based on shared publications). The different criteria grading made up a sum grade that was the base of the individual ranking that the reviewer did on overall fitness to the call.

The results of the 26 applications were shared with EB, with the short summary on the ranking, the applicants were anonymized due to existing COI with several EB members. The top 4 applications were shared (there was a clear cut of the 4 top ranking).

E. Arnér the reviewers received instructions to grade each aspect 1 (low) – 5 (high), then to give an overall grading to the applications with 1 being the highest scored one. The suggestion is to take the overall rating of each of the reviewers and average it to get the top 4 applications.

Discussions on the review procedure and ranking:

- There is difference in the rating of certain aspects between the different reviewers.
- In future calls we can set up a follow up meeting between the reviewers to score the top 5-7 applications.
- In future calls we need to be more specific on what is meant by novel collaborations.

Decision:

Due to existing COI of M. Wilhelm, M. Gerling, R. Altena, L. Lindström the decision was made on the presented anonymous ranking of the top applications.

All in favor of awarding the grant to the top 4 applications.

L. Bäckdahl will communicate the details of approved applications to the members with no COI after the meeting.

5) Update Mayo - CRKI meeting discussion (E. Arnér, 10 min) IP

E. Arnér gave a short introduction onto the ongoing collaboration between CRKI and Mayo Clinic. Cancer researchers from CRKI and Mayo clinic have an ongoing collaboration with seminars, workshops, collaborative projects and joint funding.

A strategic planning meeting is planned in May 2024 (28-29th of May) to be held in Santa Fe – USA. The meeting will have 10-15 representatives from both KI and Mayo clinic with a goal to discuss future collaborations. Program of the meeting is currently under preparation with representatives from Mayo Clinic, CRKI EB members, and some invited speakers from KI.

Invitations have been sent out and the following members will attend:

Attending in person: E. Arnér, Y. Wengström, R. Altena, S. Ekman, L. Lindström, M. Wilhelm, P. Östling, J. Fuxe, E. Jolly, Jonas Bergh, Olof Akre, Kamilla Czene

Can attend online: N. Baryawno, M. Löhr

Awaiting of answer: Janne Lehtiö



Decision:

Everyone in favor of the list, and the names will be communicated with Mayo.
Program will be shared with EB members in upcoming meetings.
Travelling options will be shared by L. Bäckdahl.

6) NIO Radiation Therapy workshop (E. Arnér, 5 min) IP

E. Arnér presented the background of the existing partnership with National Institute of Oncology in Budapest, where a memorandum has been signed in 2022 to increase the interaction, education, research and training between KI and NIO. Planning meeting has been conducted at the beginning of the year and the following was proposed:

- Radiation therapy, 3-day workshop in June 2024 to be held in NIO, Budapest. This will be coordinated by R. Altena and Alexander Waltman from CRKI side. Planning for the workshop is ongoing. Travel support will be offered to participants by CRKI, accommodation will be provided by NIO.
- PCM workshop in fall 2024, to be held in Stockholm.
- Possible travel grants for students and researchers in the future.

EB comments:

Very nice initiative if any help is needed from KCCC side E.Jolly can help.
For the radiation therapy workshop suggestion to target both clinical and pre-clinical researchers. Adamantia Fragkopoulou had a doctoral course on radiation therapy for pre-clinical researchers, she can be contacted if needed.

7) CRKI Strategy meeting in May (E. Arnér, 5 min) D

Strategy meeting to be planned in Spring to discuss what is now done at CRKI, what can we do differently and new ideas or initiatives. Strategy documents from CRKI and KCCC will be sent in advance and any topics of interest can be brought up to be added in the agenda.
The meeting will be held in combination with the EB meeting on the 21st of May.

8) Karolinska Comprehensive Cancer Center Update (P. Rossi, 5 min)

E.Jolly was appointed to present instead of P. Rossi
P. Rossi will step up as the acting hospital director over the summer, while the recruitment of the new hospital director is ongoing. Meanwhile Robert Bränström will step up as the director for the cancer theme from 4th of March. P. Rossi will stay on as the director of KCCC due to the ongoing reaccreditation. For CRKI board it is suggested to have Robert Bränström as a representative from the cancer theme.



KCCC yearly report: Yearly report of KCCC is in preparation, with data from CRKI included in this report. Each year all the activities within KCCC are shown with some qualitative aspects included. The deadline for sending for layout design and printing is 12th of February, and it will be released during KCCC day on 12th of April.

KCCC day, 12th of April: The theme for this year will be cancer prevention, with different presentations on the topic from different angles. The collaboration with Sjöberg prize and the presentation of the prize receiver will happen this year as well. The program for the day is currently in the final stages of preparation and will be shared with the registered participants. The day is open for researchers from both KI and K, with registration information to be distributed soon via the different channels.

KCCC re-accreditation: The first phase is ongoing of the first assessment; with collection of all the data and interviewing the people over the center. All the information will be sent to OEI in June. Second phase will be an audit in October. During the audit there will be a lot of interviews on both Solna and Flemingsberg campuses for KI and K, therefore it is important to find a preferable week that works.

EU projects: There are several ongoing EU projects within the cancer mission, EU for health, EU beating cancer plan, where KI is represented by CRKI. There are a lot of work being done for a big call for network of CCCs an ongoing project for 4 years where we will be working together as KCCC.

Almedalen: There has been some delays because of personnel changes in the communication departments in the hospital, but the planning is ongoing.

9) Jonas Bergh reception 20 March 18.00 The Nobel Museum IP

A reception is being planned for Jonas Bergh to thank for all the work that has been done for CRKI, invitations will be sent to previous and current EB members and some researchers in KI.

Short Break 10 min

16:12 – 16:22

10) NatiOn – National research school in clinical and translational cancer research budget presentation decision (S. Bajalica Lagercrantz, 15 min) DP

NatiOn is a joint action between KI and Uppsala University, that was initiated in 2010 and is directed towards clinical PhD students in the field of tumour biology coordinated by Svetlana Bajalica Lagercrantz. CRKI has previously contribute to the budget of the research school with 1.000.000 sek.

In previous meeting they have indicated that they would like to ask for an increase of funding from CRKI with a total of 1.450.000 sek and were asked to submit a written proposal. In the written proposal the asking for additional funding was of a total of 2.150.000 sek.

Decision is postponed and NatiOn will be contacted for a detailed explanation on the expenses and a clearer written proposal.



- 11) Task Force Grant seminar series? Instead of CRKI Clinical Cancer Talks (E. Arnér, 15 min)
E. Arnér presented a new suggestion to start a Task Force seminar, organized by the 13-funded Task Forces by CRKI. The suggested setting is a monthly seminar series, rotating scheme between the different task forces, combination of pre-clinical and clinical talks on each occasion.
L. Bäckdahl pointed out that other SFOs have similar activities for the networks they fund.

EB Comments:

- This will need a good coordination from CRKI side in order to insure the participation of all Task Forces. The planning of the time schemes and the setting to be done by CRKI and the arrangement of speakers to be done by the Task Forces.
- Emphasize the importance of targeting both clinical and pre-clinical audience.
- Both internal and external speakers can be invited.

12) Cancer Research KI organization: IP

a.) All WG leaders, update on working group progress (5 min each, 25 min total) IP

- WG1 Research (L. Lindström)
PI retreat is being finalized, the event gained a lot of interest from both junior and senior PIs. We have 80 participants and 43 talks over 2 days program.
CRKI annual retreat at Djurönäset: The scientific committee will continue this year as well, the planning of the retreat will start soon.
Discussion is ongoing on recruiting new people for the WG.
- WG2 Education (M. Wilhelm)
FoTo doctoral program: Spring courses are up and running. Two courses for preclinical students: basic tumor histopathology and the clinical oncology didn't have enough students and they had to be cancelled or moved to autumn. In the process of deciding the courses for the autumn and the biomedical master students.
International PhD student Cancer Conference, Berlin 12-14 June
planning is ongoing, 5 students will participate.
InCheck Heidelberg/Mannheim, KI workshop, June 24-27, planning ongoing.
- WG3 Outreach (Y. Wengström)
No updates
- WG4 Academic and healthcare collaboration (Vacant)
No updates
- WG5 Industrial Collaboration (S. Ekman)
Homepage for industrial collaboration is being updated in with EEO.

Industrial Seminar Series:



- (a) 5th of February on startup companies at KI, where we will have three speakers and EEO presenting.
- (b) Breakfast meeting with KI Science Park on March 13th.
- (c) Seminar with Cancer Research Horizon to be planned in March/ April.
Cancer Research Horizons: A lot of activities are ongoing there on NK cells, pediatric tumors, and SciLife collaborations.
Joint projects with KCCC focusing on industrial collaborations are being planned.

b.) Update from CRKI Reference Group (10 min, J. Fuxe) IP

The role of RG will be discussed during the strategy meeting. A preparatory meeting will be organized with RG group to get ideas and suggestions for the strategy meeting.

A point on RG will be added to the strategy meeting agenda.

13) Cancer Research KI administration update (L. Bäckdahl and D. Dabaghie, 5 min) IP

Due to the change of institutions and the delay in the official decision by KF, there has been delays in economy matters, therefore it wasn't possible to close the budget for 2023 and have the 2024 budget ready.

- Update is ongoing on the researcher's database:
 - Identified new + contacted: 70 researchers.
 - Answered the survey: 29 researchers, reminder will be sent in the beginning of February.
 - Several researchers have contacted CRKI to be added to the database.
 - Reminder to fill the survey will be sent during the week.
 - RIMS system for CRKI database, predicted date February.
 - Listing of researchers under several cancer fields will be done in the RIMS system.
- Website updates are ongoing.
- CRKI is now involved in the planning of CCE (Cancer Core Europe) summer school. Newsletter (information package) from CRH (Cancer Research Horizons) is now under revision and will be distributed to CRKI mailing list.
- The Sjöberg Foundation's call for project grants for cancer research, 2024.
Application period: 2024-02-01-2024-03-31

14) Seminar and workshops by CRKI and relevant organisations: IP

- a. Industry Collaboration Seminar, Why and How to Collaborate with Industry, 5th of February 12:00-14:00, Ragnar Granit, Biomedicum
- b. Djurönäset PI Retreat 19-20 February May 2024
- c. CRKI-Mayo collaboration Meeting 28-29 May 2024
- d. CRKI Djurönäset Retreat, 23-24 September 2024



**Karolinska
Institutet**



- e. Mayo Clinic – Karolinska Meeting 16-17 October 2024
- f. En Dag för Cancerforskning 6 November 2024

15) Cancer Research KI Executive Board Meetings Spring 2023:

7th of March 13:00-15:00, in person

24th of April 14-16, online meeting

21st of May 12-16, in person meeting

16) Any other business

We will continue with the two hours meetings format.

17) End of meeting